ClinicalTrials.gg
CompletedNCT04027387Updated Oct 6, 2021

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

A Phase 1 interventional study of TMB-365 in HIV-1-infection, sponsored by TaiMed Biologics Inc.. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-10-06.

Sponsored by TaiMed Biologics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will evaluate the safety and behavior in the body of the experimental drug TMB-365 in people with HIV-1 infection. This will be the first test of TMB-365 in humans. One dose of the study drug is given to each participant, followed by 10 weeks of monitoring for safety and levels of the drug in the blood. The first group of participants will receive the lowest dose (400 mg). If no safety concerns are seen, the next group will begin at a higher dose (800 mg). If no safety concerns are seen in the second group, the third group will begin at the highest dose in this study (1600 mg).

Read the detailed description

This phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation study will evaluate the safety, tolerability and pharmacokinetic (PK) parameters of TMB-365 administered via intravenous infusion (IV) to HIV-1 infected participants at one of three successively increasing dose levels: 400 mg, 800 mg, and 1600 mg. Each participant will be monitored for 10 weeks post-administration. All participants will be expected to participate in PK sampling during Weeks 1, 4, 5, and 6.

Beginning with the lowest dosage group, a Data Monitoring Committee (DMC) will review available data after four participants have completed two weeks of post-dose follow-up to determine if dosing of the next dosage group may proceed.

If no dose limiting toxicities (DLTs) emerge, defined as a single Grade 4 or two of the same Grade 3 clinical or laboratory adverse events deemed possibly, probably or definitely related to the study drug, or a serious adverse event deemed possibly, probably or definitely related to the study drug as graded by the DAIDS Table for Grading Severity of Adult and Pediatric Adverse Events Version 2.1, then dosing of the next higher dose group will be permitted.

Dosing in the highest dose group will begin after four of the eight participants in second group have successfully completed the scheduled study drug administration and two weeks of follow-up, and those data, along with all available data from the initial dose group have been reviewed by the DMC and no DLTs or SAEs as defined above are identified.

All participants may initiate standard combination antiretroviral therapy six weeks after receiving the study drug.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

TaiMed Biologics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years of age and no greater than 60 years on the day of Screening
  • Asymptomatic -1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Geenius™ or a second antibody test by a method other than the initial rapid HIV and/or E/CIA test, or by HIV-1 antigen, plasma HIV-1 RNA viral load
  • Has not received ART for three months prior to the first dose.
  • Screening HIV-1 RNA ≥ 1,000 copies/mL and \< 100,000 copies/mL obtained within 60 days prior to the first dose.
  • Laboratory values obtained within 60 days prior to the first dose:

    • > 10.0 g/dL
    • count ≥ 100,000/mm3
    • ≥ 1,000/mm3
    • Serum (AST) and alanine aminotransferase (ALT) \< 1.5 x (ULN)
    • (CrCl) of ≥ 50 mL/min
  • Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
  • In the opinion of the principal investigator or designee, has understood the information provided; written needs to be given before any study-related procedures are performed
  • Females of , sexually active with a male sex partner, must agree to use one effective method of from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Females of childbearing potential are female participants who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not (at least one year without menses), and are not otherwise sterile by medical evaluation.

Exclusion criteria

Exclusion Criteria:

  • Receipt of TMB-365, TROGARZO (ibalizumab-uiyk), or any anti-CD4 therapeutic (e.g., UB-421) at any time prior to the first dose
  • Pregnant, planning a pregnancy during the trial period, or lactating.
  • Known allergy/sensitivity or any to components of the study drug or its formulation, or known allergy to a MAb
  • Major psychiatric illness including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicide attempt in the previous three years
  • Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to the first dose
  • Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, high dose systemic ), vaccine, systemic cytotoxic chemotherapy, or therapy within 180 days prior to the first dose
  • Any chronic or acute medical condition, including drug use and alcohol abuse, which in the opinion of the investigator would interfere with evaluation of the study drug
  • Lack of adequate venous access
  • Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens. Note that a change in treatment regimen for intolerance is not considered treatment failure.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    TMB-365 400 mg- Group 1

    Single dose of TMB-365 400 mg or matching placebo by intravenous infusion

    Biological: TMB-365

  • Experimental
    TMB-365 800 mg- Group 2

    Single dose of TMB-365 800 mg or matching placebo by intravenous infusion

    Biological: TMB-365

  • Experimental
    TMB-365 1600 mg- Group 3

    Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion

    Biological: TMB-365

Interventions

  • BiologicalTMB-365

    An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection

06

What researchers measure

Primary outcomes

  1. Safety of a single 400mg dose of TMB-365

    % of subjects with treatment-emergent adverse events

    Time frame: 10 weeks

  2. Safety of a single 800mg dose of TMB-365

    % of subjects with treatment-emergent adverse events

    Time frame: 10 weeks

  3. Safety of a single 1600mg dose of TMB-365

    % of subjects with treatment-emergent adverse events

    Time frame: 10 weeks

  4. Pharmacokinetics of a single 400mg dose of TMB-365

    % CD4 receptor occupancy

    Time frame: 4 weeks

  5. Pharmacokinetics of a single 800mg dose of TMB-365

    % CD4 receptor occupancy

    Time frame: 4 weeks

  6. Pharmacokinetics of a single 1600mg dose of TMB-365

    % CD4 receptor occupancy

    Time frame: 4 weeks

Secondary outcomes

  1. Antiviral activity of a single 400 mg dose of TMB-365

    Change in log10 plasma HIV-1 RNA

    Time frame: 2 weeks

  2. Antiviral activity of a single 800 mg dose of TMB-365

    Change in log10 plasma HIV-1 RNA

    Time frame: 2 weeks

  3. Antiviral activity of a single 1600 mg dose of TMB-365

    Change in log10 plasma HIV-1 RNA

    Time frame: 2 weeks

07

Study locations

6 sites
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • University of Mississippi Medical Center Division of Infectious Diseases
    Jackson, Mississippi 39213, United States
  • North Texas Infectious Disease Consultants
    Dallas, Texas 75246, United States
  • Clinical Research PR, Inc
    San Juan, 00909, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Aug 2021, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 22, 2019
StartActual
Dec 14, 2019
Primary completionActual
Aug 18, 2021
CompletionActual
Aug 18, 2021
Last update
Oct 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04027387
Lead sponsor
TaiMed Biologics Inc.
Collaborators
Westat
Responsible party
Sponsor
First posted
Jul 22, 2019
Start date
Dec 14, 2019
Primary completion
Aug 18, 2021
Completion
Aug 18, 2021
Last update
Oct 6, 2021

Study contacts

Steve Weinheimer, PhD
study director · TaiMed Biologics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion